You are here: vision-research.eu » News » Newsdetails:

New potential treatment for age-related macular degeneration offers hope to patients as phase III trials begin in Bristol, UK

Patients in Bristol suffering from geographic atrophy can now enroll in the phase III clinical program for lampalizumab, a drug being investigated for this form of age-related macular degeneration (AMD).

GA is an advanced form of age-related macular degeneration (AMD), a progressive condition which can result in blindness, predominantly affecting people over the age of 70. There are more than 5 million people living with this debilitating condition worldwide and there are currently no approved treatments.